IRulya Therapeutics Inc. IRLA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026
IRulya Therapeutics Inc. (IRLA) is a healthcare company listed in the US with a market value of about $431M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.2, a 5-year average ROIC of -66%.
About IRulya Therapeutics
IRulya Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2019. It was profitable in 0 of the last 8 years in our data. Its share count rose by 50% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Net income | -$84M | -$57M | -$31M | -$52M | -$90M | -$77M | -$37M | -$12M |
| Free cash flow | -$42M | -$32M | -$18M | -$44M | -$63M | -$51M | -$33M | -$12M |
| EPS (diluted) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | $-2.63 | $-1.94 | $-3.71 |
| Net margin | — | — | — | — | — | — | — | — |
| ROIC | — | -100.7% | -34.8% | -51.2% | -75.4% | -45.7% | -33.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $76.12, 91% above the current price; targets range from $65.00 to $98.00; the consensus rating is “Strong buy”; expected EPS is $-5.00 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is IRulya Therapeutics’s P/E ratio?
About 0.2, based on the last twelve months of diluted earnings per share.
Does IRulya Therapeutics pay a dividend?
Not currently.
Is IRulya Therapeutics a good stock to buy?
We do not give buy or sell advice. IRulya Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.